Goldman Sachs Group Inc Forma Therapeutics Holdings, Inc. Transaction History

Goldman Sachs Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 May 14, 2024	BUY	$7.12 - $20.24 $962,702 - $2.74 Million	135,211 Added 72.56%	321,553 $6.42 Million
Q3 2022 Nov 10, 2022	BUY	$7.12 - $20.24 $962,702 - $2.74 Million	135,211 Added 72.56%	321,553 $6.41 Million
Q2 2022 May 14, 2024	BUY	$5.1 - $10.0 $950,344 - $1.86 Million	186,342 New	186,342 $1.28 Million
Q2 2022 Aug 15, 2022	SELL	$5.1 - $10.0 $369,209 - $723,940	-72,394 Reduced 27.98%	186,342 $1.28 Million
Q1 2022 May 16, 2022	SELL	$8.34 - $14.69 $117,735 - $207,378	-14,117 Reduced 5.17%	258,736 $2.41 Million
Q4 2021 Feb 14, 2022	BUY	$13.6 - $24.89 $1.06 Million - $1.95 Million	78,308 Added 40.25%	272,853 $3.88 Million
Q3 2021 Nov 10, 2021	BUY	$21.22 - $25.7 $4.13 Million - $5 Million	194,545 New	194,545 $4.51 Million

26.5K

Ticker FMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,860,400
Market Cap $958M
Description
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobin...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.